A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT05061147 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: MAX-40279-01

Sponsor

Maxinovel Pty., Ltd.